# Press Release

## PharmaMar Group Announces Financial Results for First Half 2025

- **The Group's total revenues increased by 18% to €95.3 million as of June 30th, 2025, versus prior year.**
- **The lurbinectedin licensing agreement for Japan signed with Merck boosted non-recurring revenues, which grew by 87% to €23 million.**
- **PharmaMar Group's recurring revenues grew by 5% during the first half of the year.**
- **EBITDA, as of June 30th reached €25.1 million, compared to -€0.8 million in the same period last year.**
- **PharmaMar Group's net profit amounted to €19.4 million as of June 30th, 2025.**

**Madrid, June 30th, 2025**.- PharmaMar Group (MSE: PHM) has reported an 18% increase in total revenue in the first six months of the year, reaching €95.3 million. Recurring revenue, resulting from the sum of net sales plus royalties received from our partners, grew by 5% as of June 30th, 2025, reaching €72.5 million.

At the end of the first half of this year, total oncology sales amounted to €45.8 million, representing a 9% increase over the same period last year. These sales include commercial sales of Yondelis® (trabectedin) in Europe, sales of raw materials to our partners for both trabectedin and lurbinectedin, distribution of Zepzelca® (lurbinectedin) under the compassionate use program ("accès compassionnel"), and commercial sales of lurbinectedin in Switzerland. The increase, during the first half of the year, was driven by the positive performance of lurbinectedin revenues in Europe, where revenues recorded under the compassionate use program – mainly in France – increased by 26% to €15.4 million, as well as commercial sales of lurbinectedin in Switzerland amounting to €8.4 million, representing a growth of 75% compared to the same period in 2024.

At the end of the first half of 2025, oncology royalty income stood at €26.4 million, compared to €26.5 million recorded on June 30th, 2024. This amount corresponds mainly to royalties received from sales of lurbinectedin by our partners Jazz Pharmaceuticals in

the US and Luye in China, which together amount to €21.0 million[1], as well as royalties from sales of trabectedin by our partners in the US and Japan, amounting to €5.4 million.

Regarding non-recurring income from licensing agreements, at the end of the first half of 2025, this increased by 87% to €23.0 million, compared to €12.3 million recorded on June 30th, 2024. The increase is driven by the lurbinectedin licensing agreement for Japan signed with Merck for €20.7 million, together with €2.0 million in deferred revenue from the 2019 agreement signed with Jazz Pharmaceuticals in relation to lurbinectedin.

During the first half of the year, €14.7 million was recognized as other net income/(expenses) corresponding to the completed portion of the Syoligo project, for which Sylentis was awarded a grant under the European IPCEI (Important Projects of Common European Interest) 'Med4Cure' program for the period January 2023 to August 2026. The total amount of the grant is €21.1 million.

The PharmaMar Group's investment in R&D amounted to €47.5 million, representing a 7% reduction compared to the first half of 2024, due to the completion of two Phase 3 clinical trials.

Of the total R&D investment for the period, the oncology segment recorded €44.8 million, compared to €46.7 million as of June 30th, 2024. This variation is mainly due to the completion in December 2024 of recruitment for the Phase 3 LAGOON clinical trial with lurbinectedin in small cell lung cancer.

For its part, the RNAi segment recorded €2.7 million in R&D as of June 30th, 2025, compared to €4.6 million for the same period last year. This variation is due to the completion in the first months of 2024 of the Phase 3 PIVO1 clinical trial with tivanisiran for dry eye.

In addition, the Company continues to invest in the clinical development of other molecules at earlier stages. In this regard, two Phase 2 clinical trials are underway with ecubectedin, as well as Phase 1 clinical trials with PM534 and PM54, all for the treatment of solid tumors.

[1]The royalties recorded for the second quarter are an estimate, as information on sales made by Jazz is not available at the date of publication of this report. Any discrepancies will be corrected in the following quarter.

As a result, the PharmaMar Group's EBITDA reached €25.1 million as of June 30th, 2025, compared to -€0.8 million in the first half of 2024.

The Group's net profit as of June 30th, 2025, stands at €19.4 million, compared to €3.5 million in the same period last year.

At the end of the first half of the year, the PharmaMar Group had cash and cash equivalents of €128.9 million, with a total financial debt of €48.3 million.

PharmaMar management will host a conference call and webcast for investors and analysts on July 31st, 2025, at 13:00 CET (07:00 AM, New York time) as follows: The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain), +1 646 664 1960 (from USA or Canada), and +44 20 3936 2999 (other countries). Participants' access code: 883194**.** Interested parties can also follow the conference call live via the following link: https://streamstudio.world-television.com/1052-1618-41957/en

The recording of the teleconference will be available for thirty days and it can be accessed on PharmaMar's website by visiting the Events Calendar section of the Company's website www.pharmamar.com



**About PharmaMar**

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

**About Yondelis®**

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

**About Zepzelca®**

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt *Ecteinascidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

**Media Contact:**

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com

Phone: +34 918466000

**Capital Markets & Investor Relations:**

José Luis Moreno– VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500